TRCT
ELTX icon

Tower Research Capital (TRC)’s Elicio Therapeutics ELTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Buy
5,286
+5,285
+528,500% +$53.1K ﹤0.01% 3523
2026
Q1 		$11 Buy
+1
New +$10 ﹤0.01% 5070
2025
Q1 		– Sell
-611
Closed -$3.12K – 5337
2024
Q4 		$3.12K Sell
611
-339
-36% -$1.67K ﹤0.01% 4713
2024
Q3 		$4.78K Buy
+950
New +$4.21K ﹤0.01% 4427
2024
Q1 		– Sell
-2,045
Closed -$17.1K – 5928
2023
Q4 		$17.1K Buy
2,045
+2,007
+5,282% +$13.1K ﹤0.01% 3750
2023
Q3 		$321 Sell
38
-131
-78% -$1.25K ﹤0.01% 5606
2023
Q2 		$1.61K Sell
169
-452
-73% -$4.15K ﹤0.01% 5349
2023
Q1 		$4K Buy
621
+263
+73% +$1.75K ﹤0.01% 5058
2022
Q4 		$3K Buy
358
+113
+46% +$1.03K ﹤0.01% 5172
2022
Q3 		$2K Buy
245
+135
+123% +$1.41K ﹤0.01% 5550
2022
Q2 		$1K Sell
110
-354
-76% -$5.65K ﹤0.01% 5775
2022
Q1 		$10K Buy
464
+43
+10% +$971 ﹤0.01% 4298
2021
Q4 		$12K Buy
421
+308
+273% +$15.6K ﹤0.01% 4269
2021
Q3 		$11K Buy
113
+4
+4% +$432 ﹤0.01% 4216
2021
Q2 		$14K Buy
109
+36
+49% +$5.19K ﹤0.01% 4170
2021
Q1 		$13K Buy
+73
New +$14.1K ﹤0.01% 4200

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ELTX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Elicio Therapeutics (ELTX) stake by 528,500% in Q2 2026, buying an estimated $53.1K and bringing the position to 5,286 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3523.

Tower Research Capital (TRC) first reported a position in ELTX in Q1 2021 and has held it in 16 quarters since. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Tower Research Capital (TRC) held 5,286 shares of Elicio Therapeutics worth $20.7K as of Q2 2026.
  • Tower Research Capital (TRC) bought 5,285 Elicio Therapeutics shares in Q2 2026, an estimated $53.1K.
  • Elicio Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3523 holding.
  • Tower Research Capital (TRC) first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.